<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922974</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-0631</org_study_id>
    <secondary_id>CDR0000646803</secondary_id>
    <secondary_id>NCI-2009-01687</secondary_id>
    <nct_id>NCT00922974</nct_id>
  </id_info>
  <brief_title>Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis</brief_title>
  <official_title>Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to
      the tumor may kill more tumor cells and cause less damage to normal tissue.

      PURPOSE: This randomized phase II/III trial is studying how well image-guided radiosurgery or
      stereotactic body radiation therapy works and compares it to external-beam radiation therapy
      in treating patients with localized spine metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the feasibility of successfully delivering image-guided radiosurgery or
           stereotactic body radiotherapy (SBRT) in patients with spine metastases in a cooperative
           group setting. (Phase II)

        -  Determine whether image-guided radiosurgery or SBRT (single dose of 16 Gy) improves pain
           control as measured by the 11-point Numerical Rating Pain Scale (NRPS) compared to
           conventional external beam radiotherapy (single dose of 8 Gy). (Phase III)

      Secondary

        -  Determine whether image-guided radiosurgery or SBRT improves the rapidity of pain
           response and increases the duration of pain response at the treated site(s) compared to
           conventional external beam radiotherapy, as measured by the NRPS. (Phase III)

        -  Compare adverse events associated with these treatment regimens, as measured by NCI
           CTCAE v3.0 criteria. (Phase III)

        -  Evaluate the long-term effects (24 months) of image-guided radiosurgery or SBRT on the
           vertebral bone (e.g., compression fracture) and the spinal cord, as measured by MRI.
           (Phase III)

      DETAILS:

      This is a multicenter, phase II study followed by a randomized phase III study. Patients
      enrolled in the phase III portion are stratified according to the number of spine metastases
      to be treated (1 vs 2-3) and the type of tumor (radioresistant [including soft tissue
      sarcomas, melanomas, and renal cell carcinomas] vs other).

      Phase II patients undergo MRI of the treated spine at baseline and at 3 months; phase III
      patients undergo MRI at baseline and at 3, 6, 12, and 24 months. Patients enrolled in the
      phase III portion also complete the Numerical Rating Pain Scale at baseline, at 1, 2, and 3
      weeks after randomization, and at 1, 3, 6, 12, and 24 months. Patients are followed after
      completion of study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2009</start_date>
  <completion_date type="Actual">April 6, 2020</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Receiving Radiosurgery/SBRT Per Protocol or With Minor Variation (Phase II)</measure>
    <time_frame>The day of protocol treatment</time_frame>
    <description>Treatment delivery was centrally reviewed by the study chair and medical physics co-chair. Success was defined as having a review of &quot;per protocol&quot; or &quot;minor variation&quot;. A 70% success rate was required for continuation to the phase III component.
Target volume compliance in is defined as the following levels of target coverage in reference to dose volume:
Per protocol: â‰¥ 90%
Minor variation: 80%-90%
Major deviation: &lt;80% of of dose volume.
Image-Guided Radiotherapy (IGRT) compliance is defined as the following differences in IGRT images between simulation/planning and treatment, as well as at the end of treatment:
Per protocol: &lt;2 mm
Minor variation: 2mm - 3mm
Major deviation: &gt; 3mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients With Complete or Partial Pain Response at 3 Months (Phase III)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Pain is measured by the Numerical Rating Pain Scale (NRPS) a numerical 11-point scale (0-10) with 0 = no pain, 1-4 = mild, 5-6 = moderate, and 7-10 = severe with 10 the worst pain imaginable. Pain response is calculated as 3 month score - baseline score with a positive value indicating increased pain and a negative value indicating decreased pain. Patients with complete or partial pain response as defined below are considered responders. The index site is the lesion with the highest baseline (day of radiosurgery) pain score. If multiple sites have the same baseline pain score, the index site is the most cephalad lesion.
Complete response: post-treatment pain score of 0 at the index site, no increase in narcotic pain medication, and no increase in pain score at the secondary treated site(s).
Partial response: post-treatment improvement of at least 3 points at the index site, no increase in narcotic pain medication, and no increase in pain score at the secondary treated site(s).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Pain Response (Phase III)</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Pain Response (Phase III)</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Adverse Events at 3 Months (Phase III)</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Adverse events (AE) were collected using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Effects (24 Months) of Treatment on the Vertebral Bone (e.g., Compression Fracture) and Spinal Cord (Phase III)</measure>
    <time_frame>Baseline, 3, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment of Cancer Therapy - General (FACT-G) Total Score at 3 Months (Phase III)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The FACT-G is a validated 27-item measure in which a higher score represents higher quality of life (QOL). Physical, functional, social and emotional well-being subscale scores are added together to form the FACT-G total score. Responses range from 0=Not a lot to 4=Very much. Certain items must be reversed before being added, by subtracting the response from 4. Subscale items are added together, multiplied by the number of items in the subscale, then divided by the number of items answered to obtain subscale totals. Total score ranges from 0-108; physical, social and functional subscales from 0-28; emotional subscale from 0-24. Each subscale requires at least 50% of the items to be completed while the overall response rate must be greater than 80%. If items are missing the subscale scores can be prorated. Change at 3 months is calculated as 3 month score - baseline score with a positive change indicating improvement in QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change Trend in the Brief Pain Inventory (BPI) Score Over 24 Months</measure>
    <time_frame>Baseline, 3, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change Trend in the EuroQol- 5 Dimension (EQ-5D) Score Over 24 Months</measure>
    <time_frame>Baseline, 3, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change Trend in the Functional Assessment of Cancer Therapy - General (FACT-G) Score Over 24 Months</measure>
    <time_frame>Baseline, 3, 12, and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">399</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Radiosurgery/SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>External Beam Radiation Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation therapy</intervention_name>
    <description>Single fraction dose of 8 Gy external beam radiation therapy</description>
    <arm_group_label>External Beam Radiation Therapy</arm_group_label>
    <other_name>EBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiosurgery/SBRT</intervention_name>
    <description>Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy. The phase III component allows 16 or 18 Gy as preferred by the treating physician.</description>
    <arm_group_label>Radiosurgery/SBRT</arm_group_label>
    <other_name>stereotactic body radiotherapy</other_name>
    <other_name>SRS</other_name>
    <other_name>stereotactic radiosurgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must have localized spine metastasis from the C1 to L5 levels by a
             screening imaging study [bone scan, positron emission tomography (PET), computerized
             tomography (CT), or magnetic resonance imaging (MRI)] (a solitary spine metastasis;
             two separate spine levels; or up to 3 separate sites [e.g., C5, T5-6, and T12] are
             permitted.) Each of the separate sites may have a maximal involvement of 2 contiguous
             vertebral bodies. Patients can have other visceral metastasis, and radioresistant
             tumors (including soft tissue sarcomas, melanomas, and renal cell carcinomas) are
             eligible. See Figure 1 in Section 3.1.1. of the protocol for a depiction of eligible
             metastatic lesions: 1) a solitary spine metastasis; 2) two contiguous spine levels
             involved; or 3) a maximum of 3 separate sites. Each of the separate sites may have a
             maximal involvement of 2 contiguous vertebral bodies. Epidural compression (arrow) is
             eligible when there is a â‰¥ 3 mm gap between the spinal cord and the edge of the
             epidural lesion (see #10). A paraspinal mass â‰¤ 5 cm is allowed (see #11).

               -  There can be multiple small metastatic lesions shown in other vertebral bodies as
                  shown in referenced diagram. The metastatic lesion of each spine should be less
                  than 20% of the vertebral body as opposed to the diffuse vertebral involvement.
                  These small lesions are often seen in the MRI even when bone scan or PET was
                  negative. Most of these lesions are not clinically required to be treated and are
                  therefore not included in the target volume of this protocol. Only the painful
                  spine (pain scoreâ‰¥ 5) is to be treated .

          2. Zubrod Performance Status 0-2;

          3. Age â‰¥ 18;

          4. History/physical examination within 2 weeks prior to registration;

          5. Negative serum pregnancy test within 2 weeks prior to registration for women of
             childbearing potential;

          6. Women of childbearing potential and male participants who are sexually active must
             agree to use a medically effective means of birth control;

          7. MRI (contrast is not required but strongly recommended) of the involved spine within 4
             weeks prior to registration to determine the extent of the spine involvement; an MRI
             is required as it is superior to a CT scan in delineating the spinal cord as well as
             identifying an epidural or paraspinal soft tissue component. Note: If an MRI was done
             as a screening imaging study for eligibility (see Section -1), the MRI can be used as
             the required MRI for treatment planning.

          8. Numerical Rating Pain Scale within 1 week prior to registration; the patient must have
             a score on the Scale of â‰¥ 5 for at least one of the planned sites for spine
             radiosurgery. Documentation of the patient's initial pain score is required. Patients
             taking medication for pain at the time of registration are eligible.

          9. Neurological examination within 1 week prior to registration to rule out rapid
             neurologic decline; see Appendix III for the standardized neurological examination.
             Patients with mild to moderate neurological signs are eligible. These neurological
             signs include radiculopathy, dermatomal sensory change, and muscle strength of
             involved extremity 4/5 (lower extremity for ambulation or upper extremity for raising
             arms and/or arm function).

         10. Patients with epidural compression are eligible provided that there is a â‰¥ 3 mm gap
             between the spinal cord and the edge of the epidural lesion.

         11. Patients with a paraspinal mass â‰¤ 5 cm in the greatest dimension and that is
             contiguous with spine metastasis are eligible.

         12. Patients must provide study specific informed consent prior to study entry.

        Exclusion Criteria:

          1. Histologies of myeloma or lymphoma;

          2. Non-ambulatory patients;

          3. Spine instability due to a compression fracture;

          4. &gt; 50% loss of vertebral body height;

          5. Frank spinal cord compression or displacement or epidural compression within 3 mm of
             the spinal cord;

          6. Patients with rapid neurologic decline;

          7. Bony retropulsion causing neurologic abnormality;

          8. Prior radiation to the index spine;

          9. Patients for whom an MRI of the spine is medically contraindicated;

         10. Patients allergic to contrast dye used in MRIs or CT scans or who cannot be
             premedicated for the use of contrast dye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Ryu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Josephine Ford Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at UC Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penrose Cancer Center at Penrose Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80933</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF St. Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center at Ball Memorial Hospital</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303-3499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center at University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Agnes Hospital Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Butterworth Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Royal Oak Campus</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic - Downtown</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107-7000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Payson Center for Cancer Care at Concord Hospital</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seacoast Cancer Center at Wentworth - Douglass Hospital</name>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <zip>03820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Health Regional Cancer Center</name>
      <address>
        <city>Pennington</city>
        <state>New Jersey</state>
        <zip>08534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-9446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Center for Cancer Care at Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44309-2090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimmel Cancer Center at Thomas Jefferson University - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC - Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center at UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Cancer Center at Lankenau Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute at University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Paul P. Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Saints Cancer Center at Wheaton Franciscan Healthcare</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Cancer Centre at McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ryu S, Pugh SL, Gerszten PC, Yin FF, Timmerman RD, Hitchcock YJ, Movsas B, Kanner AA, Berk LB, Followill DS, Kachnic LA. RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: phase 2 results. Pract Radiat Oncol. 2014 Mar-Apr;4(2):76-81. doi: 10.1016/j.prro.2013.05.001. Epub 2013 Jun 4.</citation>
    <PMID>24890347</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <results_first_submitted>February 28, 2019</results_first_submitted>
  <results_first_submitted_qc>April 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 16, 2019</results_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal bone metastases</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 23, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT00922974/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Radiosurgery/SBRT</title>
          <description>Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy. The phase III component allows 16 or 18 Gy as preferred by the treating physician.</description>
        </group>
        <group group_id="P2">
          <title>External Beam Radiation Therapy</title>
          <description>Single fraction dose of 8 Gy external beam radiation therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase II Component</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible and Started Treatment</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible, Treated, Adverse Event Data</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39">These subjects do not participate in the phase III component.</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not evaluable for treatment review</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase III Component</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="217">The phase III component accrues new subjects; these are not continuing phase II subjects.</participants>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible With 3 mo. NRPS Data</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible With 3 mo. FACT-G Data</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible With Adverse Event Data</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible, Treated, Adverse Event Data</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible registered patients</population>
      <group_list>
        <group group_id="B1">
          <title>Radiosurgery/SBRT (Phase II)</title>
          <description>Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy.</description>
        </group>
        <group group_id="B2">
          <title>Radiosurgery/SBRT (Phase III)</title>
          <description>Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase III component allows 16 or 18 Gy as preferred by the treating physician.</description>
        </group>
        <group group_id="B3">
          <title>External Beam Radiation Therapy</title>
          <description>Single fraction dose of 8 Gy external beam radiation therapy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="209"/>
            <count group_id="B3" value="130"/>
            <count group_id="B4" value="383"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="130"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="25" upper_limit="89"/>
                    <measurement group_id="B2" value="63" lower_limit="23" upper_limit="93"/>
                    <measurement group_id="B3" value="63" lower_limit="32" upper_limit="91"/>
                    <measurement group_id="B4" value="63" lower_limit="23" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="130"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="130"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="352"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="130"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="308"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Zubrod performance status</title>
          <description>Measure Description: 0 - Asymptomatic; 1 - Symptomatic but completely ambulatory; 2 - Symptomatic, &lt;50% in bed during the day; 3 - Symptomatic, &gt;50% in bed, but not bedbound; 4 - Bedbound; 5 - Death</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="130"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="220"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Numerical Rating Pain Scale (NRPS)</title>
          <description>Eleven-point scale 0-10 with 0 indicating no pain and 10 indicating the worst pain imaginable.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="130"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="B2" value="7" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="B3" value="7" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="B4" value="7" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Spine Metastases</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="130"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2-3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of Index Spine Metastasis</title>
          <description>The index site is the lesion with the highest baseline (day of radiosurgery) pain score. If multiple sites have the same baseline pain score, the index site is the most cephalad lesion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="130"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>C-1 to C-7</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-1 to T-6</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-7 to T-12</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>L-1 to L-5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of Spine Metastasis #2</title>
          <population>Subjects who had a second metastasis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>C-1 to C-7</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-1 to T-6</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-7 to T-12</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>L-1 to L-5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of Spine Metastasis #3</title>
          <population>Subjects who had a third metastasis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>T-1 to T-6</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T-7 to T-12</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>L-1 to L-5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Taking Pain Medication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="130"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Tumor</title>
          <population>This characteristic was not determined in the Phase II component.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="130"/>
                    <count group_id="B4" value="339"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Radioresistant</title>
                  <measurement_list>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intended Radiosurgery/SBRT Dose</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="130"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>16 Gy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="235"/>
                  </measurement_list>
                </category>
                <category>
                  <title>18 Gy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Receiving Radiosurgery/SBRT Per Protocol or With Minor Variation (Phase II)</title>
        <description>Treatment delivery was centrally reviewed by the study chair and medical physics co-chair. Success was defined as having a review of &quot;per protocol&quot; or &quot;minor variation&quot;. A 70% success rate was required for continuation to the phase III component.
Target volume compliance in is defined as the following levels of target coverage in reference to dose volume:
Per protocol: â‰¥ 90%
Minor variation: 80%-90%
Major deviation: &lt;80% of of dose volume.
Image-Guided Radiotherapy (IGRT) compliance is defined as the following differences in IGRT images between simulation/planning and treatment, as well as at the end of treatment:
Per protocol: &lt;2 mm
Minor variation: 2mm - 3mm
Major deviation: &gt; 3mm</description>
        <time_frame>The day of protocol treatment</time_frame>
        <population>Patients enrolled in the phase II component who were eligible and had treatment review information.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiosurgery/SBRT (Phase II)</title>
            <description>Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Receiving Radiosurgery/SBRT Per Protocol or With Minor Variation (Phase II)</title>
          <description>Treatment delivery was centrally reviewed by the study chair and medical physics co-chair. Success was defined as having a review of &quot;per protocol&quot; or &quot;minor variation&quot;. A 70% success rate was required for continuation to the phase III component.
Target volume compliance in is defined as the following levels of target coverage in reference to dose volume:
Per protocol: â‰¥ 90%
Minor variation: 80%-90%
Major deviation: &lt;80% of of dose volume.
Image-Guided Radiotherapy (IGRT) compliance is defined as the following differences in IGRT images between simulation/planning and treatment, as well as at the end of treatment:
Per protocol: &lt;2 mm
Minor variation: 2mm - 3mm
Major deviation: &gt; 3mm</description>
          <population>Patients enrolled in the phase II component who were eligible and had treatment review information.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Target volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGRT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Complete or Partial Pain Response at 3 Months (Phase III)</title>
        <description>Pain is measured by the Numerical Rating Pain Scale (NRPS) a numerical 11-point scale (0-10) with 0 = no pain, 1-4 = mild, 5-6 = moderate, and 7-10 = severe with 10 the worst pain imaginable. Pain response is calculated as 3 month score - baseline score with a positive value indicating increased pain and a negative value indicating decreased pain. Patients with complete or partial pain response as defined below are considered responders. The index site is the lesion with the highest baseline (day of radiosurgery) pain score. If multiple sites have the same baseline pain score, the index site is the most cephalad lesion.
Complete response: post-treatment pain score of 0 at the index site, no increase in narcotic pain medication, and no increase in pain score at the secondary treated site(s).
Partial response: post-treatment improvement of at least 3 points at the index site, no increase in narcotic pain medication, and no increase in pain score at the secondary treated site(s).</description>
        <time_frame>Baseline and 3 months</time_frame>
        <population>Eligible randomized patients with both baseline and 3 month NRPS scores</population>
        <group_list>
          <group group_id="O1">
            <title>Radiosurgery/SBRT (Phase III)</title>
            <description>Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase III component allows 16 or 18 Gy as preferred by the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>External Beam Radiation Therapy</title>
            <description>Single fraction dose of 8 Gy external beam radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Complete or Partial Pain Response at 3 Months (Phase III)</title>
          <description>Pain is measured by the Numerical Rating Pain Scale (NRPS) a numerical 11-point scale (0-10) with 0 = no pain, 1-4 = mild, 5-6 = moderate, and 7-10 = severe with 10 the worst pain imaginable. Pain response is calculated as 3 month score - baseline score with a positive value indicating increased pain and a negative value indicating decreased pain. Patients with complete or partial pain response as defined below are considered responders. The index site is the lesion with the highest baseline (day of radiosurgery) pain score. If multiple sites have the same baseline pain score, the index site is the most cephalad lesion.
Complete response: post-treatment pain score of 0 at the index site, no increase in narcotic pain medication, and no increase in pain score at the secondary treated site(s).
Partial response: post-treatment improvement of at least 3 points at the index site, no increase in narcotic pain medication, and no increase in pain score at the secondary treated site(s).</description>
          <population>Eligible randomized patients with both baseline and 3 month NRPS scores</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3" lower_limit="32" upper_limit="49"/>
                    <measurement group_id="O2" value="57.9" lower_limit="46" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on the one-sided exact binomial test with Î±=0.025 and a 2:1 randomization, 228 patients would be required to detect a 40% improvement in the response rate from 51% (external beam radiation therapy) to 70% (Radiosurgery/SBRT) with a statistical power of 0.80.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Pain Response (Phase III)</title>
        <time_frame>Baseline to 24 months</time_frame>
        <posting_date>04/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Duration of Pain Response (Phase III)</title>
        <time_frame>Baseline to 24 months</time_frame>
        <posting_date>04/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Adverse Events at 3 Months (Phase III)</title>
        <description>Adverse events (AE) were collected using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <population>Eligible patients with AE information</population>
        <group_list>
          <group group_id="O1">
            <title>Radiosurgery/SBRT (Phase III)</title>
            <description>Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase III component allows 16 or 18 Gy as preferred by the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>External Beam Radiation Therapy</title>
            <description>Single fraction dose of 8 Gy external beam radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Adverse Events at 3 Months (Phase III)</title>
          <description>Adverse events (AE) were collected using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</description>
          <population>Eligible patients with AE information</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="3.8" upper_limit="11.0"/>
                    <measurement group_id="O2" value="7.7" lower_limit="2.8" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" lower_limit="36.7" upper_limit="50.0"/>
                    <measurement group_id="O2" value="36.7" lower_limit="28.0" upper_limit="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients with treatment-related adverse events.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.93</p_value>
            <p_value_desc>Two-sided significance level = 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients with any adverse events.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <p_value_desc>Two-sided significance level = 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Effects (24 Months) of Treatment on the Vertebral Bone (e.g., Compression Fracture) and Spinal Cord (Phase III)</title>
        <time_frame>Baseline, 3, 12, and 24 months</time_frame>
        <posting_date>04/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Assessment of Cancer Therapy - General (FACT-G) Total Score at 3 Months (Phase III)</title>
        <description>The FACT-G is a validated 27-item measure in which a higher score represents higher quality of life (QOL). Physical, functional, social and emotional well-being subscale scores are added together to form the FACT-G total score. Responses range from 0=Not a lot to 4=Very much. Certain items must be reversed before being added, by subtracting the response from 4. Subscale items are added together, multiplied by the number of items in the subscale, then divided by the number of items answered to obtain subscale totals. Total score ranges from 0-108; physical, social and functional subscales from 0-28; emotional subscale from 0-24. Each subscale requires at least 50% of the items to be completed while the overall response rate must be greater than 80%. If items are missing the subscale scores can be prorated. Change at 3 months is calculated as 3 month score - baseline score with a positive change indicating improvement in QOL.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <population>Eligible patients who consented to QOL having both baseline and 3 month FACT-G total score.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiosurgery/SBRT (Phase III)</title>
            <description>Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase III component allows 16 or 18 Gy as preferred by the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>External Beam Radiation Therapy</title>
            <description>Single fraction dose of 8 Gy external beam radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Assessment of Cancer Therapy - General (FACT-G) Total Score at 3 Months (Phase III)</title>
          <description>The FACT-G is a validated 27-item measure in which a higher score represents higher quality of life (QOL). Physical, functional, social and emotional well-being subscale scores are added together to form the FACT-G total score. Responses range from 0=Not a lot to 4=Very much. Certain items must be reversed before being added, by subtracting the response from 4. Subscale items are added together, multiplied by the number of items in the subscale, then divided by the number of items answered to obtain subscale totals. Total score ranges from 0-108; physical, social and functional subscales from 0-28; emotional subscale from 0-24. Each subscale requires at least 50% of the items to be completed while the overall response rate must be greater than 80%. If items are missing the subscale scores can be prorated. Change at 3 months is calculated as 3 month score - baseline score with a positive change indicating improvement in QOL.</description>
          <population>Eligible patients who consented to QOL having both baseline and 3 month FACT-G total score.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="16.0"/>
                    <measurement group_id="O2" value="5.2" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming that the data are normally distributed, the two sample t-test assuming equal variances will be used to test the hypothesis at the one-sided 0.025 significance level. A mean difference of 7 points represents a clinically meaningful change (CMC). A difference of less than 7 points between the treatment arms will not be considered meaningful, even if it has statistical significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change Trend in the Brief Pain Inventory (BPI) Score Over 24 Months</title>
        <time_frame>Baseline, 3, 12, and 24 months</time_frame>
        <posting_date>04/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change Trend in the EuroQol- 5 Dimension (EQ-5D) Score Over 24 Months</title>
        <time_frame>Baseline, 3, 12, and 24 months</time_frame>
        <posting_date>04/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change Trend in the Functional Assessment of Cancer Therapy - General (FACT-G) Score Over 24 Months</title>
        <time_frame>Baseline, 3, 12, and 24 months</time_frame>
        <posting_date>04/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From randomization to last follow-up. Maximum follow-up was 30.5 months.</time_frame>
      <desc>Eligible patients who started protocol treatment and have adverse event data. Patients experiencing more than one of a given adverse event are counted only once for that adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Radiosurgery/SBRT (Phase II)</title>
          <description>Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy.</description>
        </group>
        <group group_id="E2">
          <title>Radiosurgery/SBRT (Phase III)</title>
          <description>Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase III component allows 16 or 18 Gy as preferred by the treating physician.</description>
        </group>
        <group group_id="E3">
          <title>External Beam Radiation Therapy</title>
          <description>Single fraction dose of 8 Gy external beam radiation therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Soft tissue infection [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Stoma site infection [with normal or Grade 1-2 ANC]</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain [NOS]</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain [other]</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis [with unknown ANC]</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urogenital disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-and-foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wendy Seiferheld</name_or_title>
      <organization>NRG Oncology</organization>
      <phone>215-574-3208</phone>
      <email>seiferheldw@nrgoncology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

